Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

SeaStar Medical Holding Corporation Common Stock

ICU

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Last trade $0.8423
Day change -$0.0112 (-1.31%)
Day range $0.746 – $0.915
Volume 120,896
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.52M
Price / earnings
—
Price / book
9.63×
Price / sales
2.09×
EV / sales
0.24×
EV / EBITDA
-0.04×

Profitability

Earnings per share
-$2.76
Return on assets
-276.53%
Return on equity
-3,130.92%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.03×
Quick ratio
1.02×
Cash ratio
0.82×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.22M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ICU, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$635K$615K$495K$420K$183K$338K$293K$67K
Cost of revenue$48K$54K$46K$12K$14K$27K$0$0
Gross profit$587K$561K$449K$408K$169K$311K$293K$67K
Selling, general and administrative$1.59M$1.83M$1.71M$1.22M$1.9M$1.03M$1.68M$2.1M
Research and development$3.57M$2.52M$2.34M$2.2M$1.85M$1.04M$2.43M$2.74M
Total operating expenses$5.17M$4.35M$4.05M$3.42M$3.75M$2.07M$4.12M$4.83M
Operating income-$4.58M-$3.79M-$3.6M-$3.02M-$3.58M-$1.76M-$3.82M-$4.77M
Interest expense-$2K-$8K-$6K-$13K$0-$9K-$11K$253K
Income before taxes-$4.53M-$3.73M-$3.52M-$2.9M-$3.47M-$2M-$3.77M-$4.42M
Income taxes$0$0$3K$0$0$0$3K$0
Net income-$4.53M-$3.73M-$3.52M-$2.9M-$3.47M-$2M-$3.77M-$4.42M
Net income attributable to common shareholders-$4.53M-$3.73M-$3.52M-$2.9M-$3.47M-$2M-$3.77M-$4.42M
EBITDA-$4.58M-$3.79M-$3.6M-$3.02M-$3.58M-$1.76M-$3.82M-$4.77M
Basic earnings per share-$1.03-$0.91-$0.90-$0.79-$1.30-$1.77-$4.38-$8.75
Diluted earnings per share-$1.03-$0.91-$0.90-$0.79-$1.30-$1.77-$4.38-$8.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

SeaStar Medical, a commercial-stage healthcare company, announced that it will report its Q1 2025 financial results and host a conference call on May 14, 2025. The company's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA.

GlobeNewswire Inc.

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

SeaStar Medical Holding Corporation announced that a 14th site has been activated for its NEUTRALIZE-AKI pivotal trial, which is evaluating the safety and efficacy of its Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in intensive care unit patients. The company estimates a significant market opportunity for the SCD in the AKI indication.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 5, 20261-for-10reverse split
Jun 10, 20241-for-25reverse split